The role of immunophilins in viral infection

Biochimica et Biophysica Acta - General Subjects

Volumn 1850, Issue 10, 2015, Pages 2103-2110

  Hopkins, Sam ^a   Gallay, Philippe A ^b  

^a Autoimmune Technologies LLC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cyclophilin inhibitors; Cyclophilins; HCV; HIV 1; Immunophilins; Viruses

Indexed keywords

ALISPORIVIR; CYCLOPHILIN; CYCLOPHILIN 40; CYCLOPHILIN A; CYCLOPHILIN B; CYCLOPHILIN C; CYCLOPHILIN D; CYCLOPHILIN E; CYCLOPHILIN G; CYCLOPHILIN H; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYCLOSPORIN D; CYCLOSPORIN DERIVATIVE; NVP 018; SCY 635; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CORONAVIRIDAE; CYTOMEGALOVIRUS; DENGUE VIRUS; DRUG RECEPTOR BINDING; DRUG TARGETING; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PAPILLOMAVIRUS TYPE 16; INFLUENZA A VIRUS; INNATE IMMUNITY; JAPANESE ENCEPHALITIS VIRUS; MOLECULAR PROBE; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VESICULOVIRUS; VIRION; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS UNCOATING; VIRUS VIRULENCE; YELLOW FEVER VIRUS; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; PATHOGENICITY; PHYSIOLOGY; RNA VIRUS; RNA VIRUS INFECTION;

ANIMALS; CYCLOPHILIN A; HUMANS; RNA VIRUS INFECTIONS; RNA VIRUSES; RNA, VIRAL; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84940594846     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2014.11.011     Document Type: Article

References (88)

1. A. Phillips, M.A. Wainberg, R. Coates, M. Klein, A. Rachlis, S. Read, F. Shepherd, H. Vellend, S. Walmsley, P. Halloran, and et al. Cyclosporine-induced deterioration in patients with AIDS CMAJ 140 1989 1456 1460
2. A. Karpas, M. Lowdell, S.K. Jacobson, and F. Hill Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506 Proc. Natl. Acad. Sci. U. S. A. 89 1992 8351 8355
3. J. Luban, K.L. Bossolt, E.K. Franke, G.V. Kalpana, and S.P. Goff Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B Cell 73 1993 1067 1078
4. E.K. Franke, H.E. Yuan, and J. Luban Specific incorporation of cyclophilin A into HIV-1 virions Nature 372 1994 359 362
5. M. Thali, A. Bukovsky, E. Kondo, B. Rosenwirth, C.T. Walsh, J. Sodroski, and H.G. Göttlinger Functional association of cyclophilin A with HIV-1 virions Nature 372 1994 363 365
6. B. Rosenwirth, A. Billich, R. Datema, P. Donatsch, F. Hammerschmid, R. Harrison, P. Hiestand, H. Jaksche, P. Mayer, P. Peichl, and et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog Antimicrob. Agents Chemother. 38 1763-1772
7. A. Billich, F. Hammerschmid, P. Peichl, R. Wenger, G. Zenke, V. Quesniaux, and B. Rosenwirth Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions J. Virol. 69 1995 2451 2461
8. T.R. Gamble, F.F. Vajdos, S. Yoo, D.K. Worthylake, M. Houseweart, W.I. Sundquist, and C.P. Hill Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid Cell 87 1996 1285 1294
9. S. Yoo, D.G. Myszka, C. Yeh, M. McMurray, C.P. Hill, and W.I. Sundquist Molecular recognition in the HIV-1 capsid/cyclophilin A complex J. Mol. Biol. 269 1997 780 795
10. D. Braaten, H. Ansari, and J. Luban The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein J. Virol. 71 1997 2107 2113
11. T. Dorfman, A. Weimann, A. Borsetti, C.T. Walsh, and H.G. Göttlinger Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions J. Virol. 71 1997 7110 7113
12. A.A. Bukovsky, A. Weimann, M.A. Accola, and H.G. Göttlinger Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence Proc. Natl. Acad. Sci. U. S. A. 94 1997 10943 10948
13. D. Braaten, and J. Luban Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells EMBO J. 20 2001 1300 1309
14. N.A. Kootstra, C. Munk, N. Tonnu, N.R. Landau, and I.M. Verma Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 1298 1303
15. D.A. Bosco, E.Z. Eisenmesser, S. Pochapsky, W.I. Sundquist, and D. Kern Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A Proc. Natl. Acad. Sci. U. S. A. 99 2002 5247 5252
16. G.J. Towers, T. Hatziioannou, S. Cowan, S.P. Goff, J. Luban, and P.D. Bieniasz Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors Nat. Med. 9 2003 1138 1143
17. M.J. Perron, M. Stremlau, B. Song, W. Ulm, R.C. Mulligan, and J. Sodroski TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 11827 11832
18. D.M. Sayah, E. Sokolskaja, L. Berthoux, and J. Luban Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1 Nature 430 2004 569 573
19. S. Nisole, C. Lynch, J.P. Stoye, and M.W. Yap A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1 Proc. Natl. Acad. Sci. U. S. A. 101 2004 13324 13328
20. S.J. Wilson, B.L. Webb, L.M. Ylinen, E. Verschoor, J.L. Heeney, and G.J. Towers Independent evolution of an antiviral TRIMCyp in rhesus macaques Proc. Natl. Acad. Sci. U. S. A. 105 2008 3557 3562 10.1073/pnas.0709003105
21. L. Berthoux, S. Sebastian, E. Sokolskaja, and J. Luban Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells Proc. Natl. Acad. Sci. U. S. A. 102 2005 14849 14853
22. R.G. Ptak, P.A. Gallay, D. Jochmans, A.P. Halestrap, U.T. Ruegg, L.A. Pallansch, M.D. Bobardt, M.P. de Béthune, J. Neyts, E. De Clercq, J.M. Dumont, P. Scalfaro, K. Besseghir, R.M. Wenger, and B. Rosenwirth Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Antimicrob. Agents Chemother. 52 2008 1302 1317 10.1128/AAC. 01324-07
23. U. Chatterji, M.D. Bobardt, R. Stanfield, R.G. Ptak, L.A. Pallansch, P.A. Ward, M.J. Jones, C.A. Stoddart, P. Scalfaro, J.M. Dumont, K. Besseghir, B. Rosenwirth, and P.A. Gallay Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells J. Biol. Chem. 280 2005 40293 40300
24. K.A. Matreyek, and A. Engelman The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid J. Virol. 85 2011 7818 7827 10.1128/JVI. 00325-11
25. T. Schaller, K.E. Ocwieja, J. Rasaiyaah, A.J. Price, T.L. Brady, S.L. Roth, S. Hué, A.J. Fletcher, K. Lee, V.N. KewalRamani, M. Noursadeghi, R.G. Jenner, L.C. James, F.D. Bushman, and G.J. Towers HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency PLoS Pathog. 7 2011 e1002439 10.1371/journal.ppat.1002439
26. F. Di Nunzio, A. Danckaert, T. Fricke, P. Perez, J. Fernandez, E. Perret, P. Roux, S. Shorte, P. Charneau, F. Diaz-Griffero, and N.J. Arhel Human nucleoporins promote HIV-1 docking at the nuclear pore, nuclear import and integration PLoS ONE 7 2012 e46037 10.1371/journal.pone.0046037
27. V.B. Shah, J. Shi, D.R. Hout, I. Oztop, L. Krishnan, J. Ahn, M.S. Shotwell, A. Engelman, and C. Aiken The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating J. Virol. 87 2013 422 432 10.1128/JVI. 07177-11
28. C.A. Guth, and J. Sodroski Contribution of PDZD8 to stabilization of the human immunodeficiency virus type 1 capsid J. Virol. 88 2014 4612 4623 10.1128/JVI. 02945-13
29. A.J. Price, A.J. Fletcher, T. Schaller, T. Elliott, K. Lee, V.N. KewalRamani, J.W. Chin, G.J. Towers, and L.C. James CPSF6 defines a conserved capsid interface that modulates HIV-1 replication PLoS Pathog. 8 2012 e1002896 10.1371/journal.ppat.1002896
30. K. Bichel, A.J. Price, T. Schaller, G.J. Towers, S.M. Freund, and L.C. James HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358 Retrovirology 10 2013 10.1186/1742-4690-10-81
31. N. Manel, B. Hogstad, Y. Wang, D.E. Levy, D. Unutmaz, and D.R. Littman A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells Nature 467 2010 214 217 10.1038/nature09337
32. J. Rasaiyaah, C.P. Tan, A.J. Fletcher, A.J. Price, C. Blondeau, L. Hilditch, D.A. Jacques, D.L. Selwood, L.C. James, M. Noursadeghi, and G.J. Towers HIV-1 evades innate immune recognition through specific cofactor recruitment Nature 503 2013 402 405 10.1038/nature12769
33. A.L. Cox, and R.F. Siliciano Making sense of HIV innate sensing Immunity 39 2013 998 1000 10.1016/j.immuni.2013.11.014
34. Z. Liu, Q. Pan, S. Ding, J. Qian, F. Xu, J. Zhou, S. Cen, F. Guo, and C. Liang The interferon-inducible MxB protein inhibits HIV-1 infection Cell Host Microbe 14 2013 398 410 10.1016/j.chom.2013.08.015
35. P.A. Gallay, R.G. Ptak, M.D. Bobardt, J.M. Dumont, G. Vuagniaux, and B. Rosenwirth Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms Viruses 5 2013 981 997 10.3390/v5030981
36. S. Teraoka, S. Mishiro, K. Ebihara, T. Sanaka, Y. Yamaguchi, I. Nakajima, T. Kawai, T. Yagisawa, H. Honda, S. Fuchinoue, and et al. Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus Transplant. Proc. 20 1988 868 876
37. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
38. M. Nakagawa, N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C.H. Chen, Y. Itsui, S. Kakinuma, and M. Watanabe Specific inhibition of hepatitis C virus replication by cyclosporin A Biochem. Biophys. Res. Commun. 313 2004 42 47
39. K. Goto, K. Watashi, T. Murata, T. Hishiki, M. Hijikata, and K. Shimotohno Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811 Biochem. Biophys. Res. Commun. 343 2006 879 884
40. N. Ishii, K. Watashi, T. Hishiki, K. Goto, D. Inoue, M. Hijikata, T. Wakita, N. Kato, and K. Shimotohno Diverse effects of cyclosporine on hepatitis C virus strain replication J. Virol. 80 2006 4510 4520
41. M. Nakagawa, N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C.H. Chen, S. Kakinuma, S. Oooka, S. Maekawa, N. Enomoto, and M. Watanabe Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins Gastroenterology 129 2005 1031 1041
42. K. Watashi, N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase Mol. Cell 19 2005 111 122
43. L.A. Gaither, J. Borawski, L.J. Anderson, K.A. Balabanis, P. Devay, G. Joberty, C. Rau, M. Schirle, T. Bouwmeester, C. Mickanin, S. Zhao, C. Vickers, L. Lee, G. Deng, J. Baryza, R.A. Fujimoto, K. Lin, T. Compton, and B. Wiedmann Multiple cyclophilins involved in different cellular pathways mediate HCV replication Virology 397 2010 43 55 10.1016/j.virol.2009.10.043
44. F. Yang, J.M. Robotham, H.B. Nelson, A. Irsigler, R. Kenworthy, and H. Tang Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro J. Virol. 82 2008 5269 5278 10.1128/JVI. 02614-07
45. U. Chatterji, M. Bobardt, S. Selvarajah, F. Yang, H. Tang, N. Sakamoto, G. Vuagniaux, T. Parkinson, and P. Gallay The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J. Biol. Chem. 284 2009 16998 17005 10.1074/jbc.M109.007625
46. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, S. Kallis, M. Zayas, V. Lohmann, J. Luban, and R. Bartenschlager Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog. 5 2009 e1000546 10.1371/journal.ppat.1000546
47. M. Dorner, J.A. Horwitz, B.M. Donovan, R.N. Labitt, W.C. Budell, T. Friling, A. Vogt, M.T. Catanese, T. Satoh, T. Kawai, S. Akira, M. Law, C.M. Rice, and A. Ploss Completion of the entire hepatitis C virus life cycle in genetically humanized mice Nature 501 2013 237 241 10.1038/nature12427
48. S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, and K. Lin NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrob. Agents Chemother. 50 2006 2976 2982
49. J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
50. S. Hopkins, B. Scorneaux, Z. Huang, M.G. Murray, S. Wring, C. Smitley, R. Harris, F. Erdmann, G. Fischer, and Y. Ribeill SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob. Agents Chemother. 54 2010 660 672 10.1128/AAC. 00660-09
51. R. Flisiak, A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, J. Kierkus, C. Aeschlimann, P. Grosgurin, V. Nicolas-Métral, J.M. Dumont, H. Porchet, R. Crabbé, and P. Scalfaro The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826 10.1002/hep.22131
52. S. Hopkins, B. DiMassimo, P. Rusnak, D. Heuman, J. Lalezari, A. Sluder, B. Scorneaux, S. Mosier, P. Kowalczyk, Y. Ribeill, J. Baugh, and P. Gallay The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection J. Hepatol. 57 2012 47 54 10.1016/j.jhep.2012.02.024
53. S. Hopkins, and P. Gallay Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection Viruses 4 2012 2558 2577 10.3390/v4112558
54. P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Des. Dev. Ther. 7 2013 105 115 10.2147/DDDT.S30946
55. J.M. Robida, H.B. Nelson, Z. Liu, and H. Tang Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro J. Virol. 81 2007 5829 5840
56. F. Fernandes, D.S. Poole, S. Hoover, R. Middleton, A.C. Andrei, J. Gerstner, and R. Striker Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B Hepatology 46 2007 1026 1033
57. K. Goto, K. Watashi, D. Inoue, M. Hijikata, and K. Shimotohno Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor Cancer Sci. 100 2009 1943 1950 10.1111/j.1349-7006.2009.01263.x
58. X. Puyang, D.L. Poulin, J.E. Mathy, L.J. Anderson, S. Ma, Z. Fang, S. Zhu, K. Lin, R. Fujimoto, T. Compton, and B. Wiedmann Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors Antimicrob. Agents Chemother. 54 2010 1981 1987 10.1128/AAC. 01236-09
59. Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J. Virol. 83 2009 6554 6565 10.1128/JVI. 02550-08
60. T.L. Foster, P. Gallay, N.J. Stonehouse, and M. Harris Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J. Virol. 85 2011 7460 7464 10.1128/JVI. 00393-11
61. A. Nag, J.M. Robotham, and H. Tang Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors J. Virol. 86 2012 12616 12624 10.1128/JVI. 01351-12
62. J.A. Heck, X. Meng, and D.N. Frick Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase Biochem. Pharmacol. 77 2009 1173 1180 10.1016/j.bcp.2008.12.019
63. X. Hanoulle, A. Badillo, J.M. Wieruszeski, D. Verdegem, I. Landrieu, R. Bartenschlager, F. Penin, and G. Lippens Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J. Biol. Chem. 284 2009 13589 13601 10.1074/jbc.M809244200
64. F. Yang, J.M. Robotham, H. Grise, S. Frausto, V. Madan, M. Zayas, R. Bartenschlager, M. Robinson, A.E. Greenstein, A. Nag, T.M. Logan, E. Bienkiewicz, and H. Tang A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach PLoS Pathog. 6 2010 e1001118 10.1371/journal.ppat.1001118
65. H. Grisé, S. Frausto, T. Logan, and H. Tang A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility J. Virol. 86 2012 4811 4822 10.1128/JVI. 06641-11
66. D. Verdegem, A. Badillo, J.M. Wieruszeski, I. Landrieu, A. Leroy, R. Bartenschlager, F. Penin, G. Lippens, and X. Hanoulle Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A J. Biol. Chem. 286 2011 20441 20454 10.1074/jbc.M110.182436
67. I.U. Ansari, and R. Striker Subtype specific differences in NS5A domain II reveals involvement of proline at position 310 in cyclosporine susceptibility of hepatitis C virus Viruses 4 2012 3303 3315
68. U. Chatterji, P. Lim, M.D. Bobardt, S. Wieland, D.G. Cordek, G. Vuagniaux, F. Chisari, C.E. Cameron, P. Targett-Adams, T. Parkinson, and P.A. Gallay HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors J. Hepatol. 53 2010 50 56 10.1016/j.jhep.2010.01.041
69. M.A. Gregory, M. Bobardt, S. Obeid, U. Chatterji, N.J. Coates, T. Foster, P. Gallay, P. Leyssen, S.J. Moss, J. Neyts, M. Nur-e-Alam, J. Paeshuyse, M. Piraee, D. Suthar, T. Warneck, M.Q. Zhang, and B. Wilkinson Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family Antimicrob. Agents Chemother. 55 2011 1975 1981 10.1128/AAC.01627-10
70. L. Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, G. Vuagniaux, A.M. Vandamme, R. Bartenschlager, P. Gallay, G. Lippens, and J. Neyts DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS ONE 5 2010 e13687 10.1371/journal.pone.0013687
71. J.A. Garcia-Rivera, M. Bobardt, U. Chatterji, S. Hopkins, M.A. Gregory, B. Wilkinson, K. Lin, and P.A. Gallay Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir Antimicrob. Agents Chemother. 56 2012 5113 5121 10.1128/AAC. 00919-12
72. L.J. Anderson, K. Lin, T. Compton, and B. Wiedmann Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion Virol. J. 8 2011 329 10.1186/1743-422X-8-329
73. I. Romero-Brey, and R. Bartenschlager Membranous replication factories induced by plus-strand RNA viruses Viruses 6 2014 2826 2857 10.3390/v6072826
74. V. Madan, D. Paul, V. Lohmann, and R. Bartenschlager Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation Gastroenterology 146 2014 1361 1372 10.1053/j.gastro.2014.01.055 (e1-9)
75. U. Chatterji, M.D. Bobardt, M. Wood, and P.A. Gallay Alisporivir specifically eliminates HCV-created double membrane vesicles in infected hepatocytes by disrupting CypA-NS5A interactions 21th International Symposium on Hepatitis C Virus And Related Viruses, Banff Canada 2014 (Abstract # P.3.54)
76. X. Tian, C. Zhao, H. Zhu, W. She, J. Zhang, J. Liu, L. Li, S. Zheng, Y.M. Wen, and Y. Xie Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection J. Virol. 84 2010 3373 3381 10.1128/JVI. 02555-09
77. M.J. Hansson, S.J. Moss, M. Bobardt, U. Chatterji, N. Coates, J.A. Garcia-Rivera, E. Elmér, S. Kendrew, P. Leyssen, M. Nur-E-Alam, T. Warneck, B. Wilkinson, P.A. Gallay, and M.A. Gregory Bioengineering and semisynthesis combined to generate an optimized natural product cyclophilin inhibitor for treatment of chronic HBV, HCV and HIV infection Chem. Biol. 2014 (in press)
78. S. Chokshi, S. Phillips, A. Riva, and N. Naoumov Alisporivir inhibition of cellular cyclophilins disrupts hepatitis B virus (HBV) replication and this effect is further enhanced in combination with direct antiviral targeting HBV-DNA polymerase in vitro Gut 61 2012 A11 10.1136/gutjnl-2012-302514a.25
79. J. Carbajo-Lozoya, Y. Ma-Lauer, M. Malešević, M. Theuerkorn, V. Kahlert, E. Prell, B. von Brunn, D. Muth, T.F. Baumert, C. Drosten, G. Fischer, and A. von Brunn Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir Virus Res. 184 2014 44 53 10.1016/j.virusres.2014.02.010
80. A.H. de Wilde, J.C. evenhoven-Dobbe, Y. van der Meer, V. Thiel, K. Narayanan, S. Makino, E.J. Snijder, and M.J. van Hemert Cyclosporin A inhibits the replication of diverse coronaviruses J. Gen. Virol. 92 2011 2542 2548 10.1099/vir.0.034983-0
81. H. Kawasaki, E.S. Mocarski, I. Kosugi, and Y. Tsutsui Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells J. Virol. 81 2007 9013 9023
82. L.R. Keyes, M.G. Bego, M. Soland, and S. St Jeor Cyclophilin A is required for efficient human cytomegalovirus DNA replication and reactivation J. Gen. Virol. 93 2012 722 732 10.1099/vir. 0.037309-0
83. H. Kambara, H. Tani, Y. Mori, T. Abe, H. Katoh, T. Fukuhara, S. Taguwa, K. Moriishi, and Y. Matsuura Involvement of cyclophilin B in the replication of Japanese encephalitis virus Virology 412 2011 211 219 10.1016/j.virol.2011.01.011
84. M. Bienkowska-Haba, H.D. Patel, and M. Sapp Target cell cyclophilins facilitate human papillomavirus type 16 infection PLoS Pathog. 5 2009 e1000524 10.1371/journal.ppat.1000524
85. S. Bose, M. Mathur, P. Bates, N. Joshi, and A.K. Banerjee Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype J. Gen. Virol. 84 2003 1687 1699
86. X. Liu, Z. Zhao, C. Xu, L. Sun, J. Chen, L. Zhang, and W. Liu Cyclophilin A restricts influenza A virus replication through degradation of the M1 protein PLoS ONE 7 2012 e31063 10.1371/journal.pone.0031063
87. X. Liu, Z. Zhao, Z. Li, C. Xu, L. Sun, J. Chen, and W. Liu Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways PLoS ONE 7 2012 e37277 10.1371/journal.pone.0037277
88. M. Qing, F. Yang, B. Zhang, G. Zou, J.M. Robida, Z. Yuan, H. Tang, and P.Y. Shi Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein Antimicrob. Agents Chemother. 53 2009 3226 3235 10.1128/AAC. 00189-09